Day One Biopharma shares retain overweight rating on ojemda drug usage By Investing.com

Retrieved on: 2024-10-23 15:25:19

Tags for this article:

Click the tags to see associated articles and topics

Day One Biopharma shares retain overweight rating on ojemda drug usage By Investing.com. View article details on hiswai:

Excerpt

Day One Biopharmaceuticals' (NASDAQ:DAWN) strong market performance, as highlighted by Piper Sandler's analysis, is reflected in some of the company's ...

Article found on: www.investing.com

View Original Article